Genmab A/S (GMAB)

NASDAQ: GMAB · Real-Time Price · USD
32.74
+0.10 (0.31%)
At close: Oct 8, 2025, 4:00 PM EDT
32.74
0.00 (0.00%)
After-hours: Oct 8, 2025, 4:10 PM EDT
0.31%
Market Cap20.11B
Revenue (ttm)3.65B
Net Income (ttm)1.37B
Shares Out 61.50M
EPS (ttm)21.62
PE Ratio1.51
Forward PE20.93
Dividendn/a
Ex-Dividend Daten/a
Volume1,568,634
Open32.78
Previous Close32.64
Day's Range32.51 - 32.93
52-Week Range17.24 - 33.63
Beta0.82
AnalystsStrong Buy
Price Target41.17 (+25.75%)
Earnings DateNov 5, 2025

About GMAB

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large Bcell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell no... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 2,682
Stock Exchange NASDAQ
Ticker Symbol GMAB
Full Company Profile

Financial Performance

In 2024, Genmab's revenue was $2.99 billion, an increase of 22.32% compared to the previous year's $2.44 billion. Earnings were $1.09 billion, an increase of 68.72%.

Financial Statements

Analyst Summary

According to 7 analysts, the average rating for GMAB stock is "Strong Buy." The 12-month stock price target is $41.17, which is an increase of 25.75% from the latest price.

Price Target
$41.17
(25.75% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

MERUS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Merus N.V. - MRUS

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Merus...

Other symbols: MRUS
7 days ago - Business Wire

Genmab A/S (GMAB) M&A Call Transcript

Genmab A/S (GMAB) M&A Call September 29, 2025 7:00 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Tahamtan Ahmadi - Executive VP, Chief Medical Officer & Head of Experimen...

8 days ago - Seeking Alpha

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

Genmab A/S (NASDAQ: GMAB) on Monday agreed to acquire Merus N.V. (NASDAQ: MRUS) with its late-stage asset petosemtamab, which is in Phase 3 development, for $97 per share in an all-cash transaction re...

Other symbols: MRUS
9 days ago - Benzinga

This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.

Genmab will acquire Merus in an all-cash transaction worth around $8 billion.

Other symbols: MRUS
9 days ago - Barrons

Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline

Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi...

Other symbols: MRUS
9 days ago - Invezz

Genmab to buy Dutch cancer drugmaker Merus for $8 billion

Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.

Other symbols: MRUS
9 days ago - Reuters

Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model

COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi...

Other symbols: MRUS
9 days ago - Business Wire

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants t...

12 days ago - GlobeNewsWire

Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Anthony Pagano - Executive VP & CFO Conference Call Participants Sachin Jain - B...

13 days ago - Seeking Alpha

Major Shareholder Announcement

Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Mar...

15 days ago - GlobeNewsWire

Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy

Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-...

24 days ago - Seeking Alpha

Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff

Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl...

26 days ago - Seeking Alpha

Genmab: A Matter Of Time

Genmab raised the full-year revenue and operating income guidance after strong Q2 results, driven by robust royalty streams and growing net sales of Epkinly and Tivdak. Genmab's maturing and expanding...

26 days ago - Seeking Alpha

Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Genmab A/S (GMAB) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive ...

4 weeks ago - Seeking Alpha

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,...

4 weeks ago - GlobeNewsWire

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The inc...

4 weeks ago - GlobeNewsWire

10 stocks to consider if you want alternatives to the expensive S&P 500

Stocks in developed economies outside the U.S. tend to trade at lower valuations. Some of the companies are expected to expand their businesses rapidly over the next two years.

Other symbols: SPYAEGEFANGG
4 weeks ago - Market Watch

Genmab Announces Updated Results from Phase 2 EPCORE® NHL-6 Study Evaluating Epcoritamab Monotherapy in the Outpatient Setting in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced updated results from the Phase 2 EPCORE® NHL-6 trial (NCT05451810) evaluating the safety and efficacy of investigational...

5 weeks ago - Business Wire

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and C hief F inancial O fficer Anthony Pagano will part...

6 weeks ago - GlobeNewsWire

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart sesute...

6 weeks ago - Business Wire

Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%

Genmab A/S GMAB released results Thursday of the Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide (R2) versus R2 alone for adult patients wi...

Other symbols: ABBV
2 months ago - Benzinga

Genmab A/S (GMAB) Q2 2025 Earnings Call Transcript

Genmab A/S (GMAB) Q2 2025 Earnings Conference Call August 7, 2025 12:00 PM ET Company Participants Anthony Pagano - Executive VP & CFO Brad Bailey - Corporate Participant Jan G.J. van de Winkel - Co-F...

2 months ago - Seeking Alpha

Genmab Announces Financial Results for the First Half of 2025

August 7, 2025 Copenhagen, Denmark; Interim Report for the First Half Ended June 30, 2025 Highlights Epcoritamab a dvancing to earlier lines of therapy with the submission of a sBLA to the FDA for epc...

2 months ago - GlobeNewsWire

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in combin...

2 months ago - Business Wire

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

2 months ago - CNBC Television